Hybrid Cell Vaccination in Metastatic Melanoma: Clinical and Immunologic Results of a Phase I/II Study

Journal of Immunotherapy

Volumn 27, Issue 2, 2004, Pages 147-155

  Haenssle, Holger A ^a   Krause, Stefan W ^b   Emmert, Steffen ^a   Zutt, Markus ^a   Kretschmer, Lutz ^a   Schmidberger, Heinz ^a   Andreesen, Reinhard ^b   Soruri, Afsaneh ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cell fusion; Clinical trial; Dendritic cells; Hybrid cells; Melanoma; Therapy; Vaccination

Indexed keywords

CANCER VACCINE; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUSION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE COURSE; DRUG SAFETY; DRUG SYNTHESIS; EDEMA; ELECTROFUSION (CELL); ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; HYBRID CELL; IMMUNE RESPONSE; INJECTION PAIN; LOW DRUG DOSE; MALE; MELANOMA; MELANOMA CELL; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN INDURATION; VACCINATION;

EID: 1442336031     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200403000-00008     Document Type: Article

References (48)

1. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
2. Letsch A, Keilholz U, Schadendorf D, et al. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int J Cancer. 2000;87:659-664.
3. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol. 1996;8:628-636.
4. Becker JC, Schwinn A, Dummer R, et al. Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells: induction of proliferation and cytokine production. J Invest Dermatol. 1993;101:15-21.
5. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today. 1995;16:334-336.
6. Brocker EB, Zwadlo G, Holzmann B, et al. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer. 1988;41:562-567.
7. Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991;97:197-202.
8. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. Immunol. 1989;142:3714-3725.
9. Van den EB, Hainaut P, Herin M, et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer. 1989;44:634-640.
10. Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273.
11. Phan GQ, Wang E, Marincola FM. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther. 2001;1:511-523.
12. Roth C, Roehlitz C, Kourilsky P. Immune response against tumors. Adv Immunol. 1994;57:281-351.
13. Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest. 1999;104:173-180.
14. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-251.
15. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
16. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669-1678.
17. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother. 2002;25:289-303.
18. Cao X, Zhang W, Wang J, et al. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology. 1999;97:616-625.
19. Wang RF. Human tumor antigens: implications for cancer vaccine development. J Mol Med. 1999;77:640-655.
20. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561.
21. Guo Y, Wu M, Chen H, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 1994;263:518-520.
22. Stuhler G, Walden P. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes. Cancer Immunol Immunother. 1994;39:342-345.
23. Trefzer U, Weingart G, Chen Y, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 2000;85:618-626.
24. Soruri A, Fayyazi A, Gieseler R, et al. Specific autologous anti-melanoma T cell response in vitro using monocyte-derived dendritic cells. Immunobiology. 1998;198:527-538.
25. Soruri A, Fayyazi A, Neumann C, et al. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dendritic cell/melanoma cell hybridomas. Cancer Immunol Immunother. 2001;50:307-314.
26. Andreesen R, Scheibenbogen C, Brugger W, et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 1990;50:7450-7456.
27. Zimmermann U, Vienken J. Electric field-induced cell-to-cell fusion. J Membr Biol. 1982;67:165-182.
28. Jung T, Schauer U, Rieger C, et al. Interleukin-4 and interleukin-5 are rarely co-expressed by human T cells. Eur J Immunol. 1995;25:2413-2416.
29. Sato T, McCue P, Masuoka K, et al. Interleukin 10 production by human melanoma. Clin Cancer Res. 1996;2:1383-1390.
30. Fabre JW. The allogeneic response and tumor immunity. Nat Med. 2001:7:649-652.
31. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 1999;59:3340-3345.
32. Mackensen A, Krause T, Blum U, et al. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother. 1999;48:118-122.
33. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56-58.
34. Moller P, Sun Y, Dorbic T, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer. 1998;77:1907-1916.
35. Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase 1 study. Gene Ther. 1998;5:481-490.
36. Li J, Holmes LM, Franck KJ, et al. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother. 2001;50:456-462.
37. Holmes LM, Li J, Sticca RP, et al. A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J Immunother. 2001;24:122-129.
38. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021-1032.
39. Zhang W, He L, Yuan Z, et al. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum Gene Ther. 1999;10:1151-1161.
40. Jenne L, Arrighi JF, Jonuleit H, et al. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis. Cancer Res. 2000;60:4446-4452.
41. Chen Q, Daniel V, Maher DW, et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer. 1994;56:755-760.
42. Dummer W, Bastian BC, Ernst N, et al. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer. 1996;66:607-610.
43. McBride JM, Jung T, de Vries JE, et al. IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses. Cell Immunol. 2002;215:162-172.
44. Lotze MT, Hellerstedt B, Stolinski L, et al. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J Sci Am. 1997;3(suppl 1):S109-S114.
45. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am. 2000;6(suppl 1):S8-10.
46. Atkins MB. Interleukin-2: clinical applications. Semin Oncol. 2002;29:12-17.
47. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci U S A. 1999;96:2268-2273.
48. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907-913.